The core pathological changes in chronic hepatitis B are hepatic inflammation and hepatocellular necrosis, which are fundamentally caused by immune-mediated liver injury triggered by persistent replication of the hepatitis B virus. Entecavir Capsules exert potent inhibition on viral replication, reducing viral colonization and spread within hepatocytes. This not only diminishes direct viral damage to hepatocytes but also mitigates the body's immune attack on virus-infected hepatocytes, thereby relieving hepatic inflammatory responses.

In clinical practice, following administration of it, as serum HBV-DNA levels decline, patients' serum transaminase (ALT/AST) levels gradually return to normal. Transaminases are key indicators reflecting hepatic inflammation; their normalization signifies effective control of liver inflammation, reduced hepatocellular necrosis, and gradual recovery of the liver's metabolic and detoxification functions. For chronic hepatitis B patients with abnormal liver function, it rapidly improve liver function, relieve clinical symptoms such as fatigue, anorexia, abdominal distension and hepatic discomfort, and enhance patients' quality of life.

Prolonged hepatic inflammation and hepatocellular necrosis lead to proliferation of hepatic fibrous tissue and progressive development of hepatic fibrosis. Without timely intervention, this condition may further advance to liver cirrhosis and even hepatocellular carcinoma. Through long-term, potent suppression of viral replication and sustained alleviation of hepatic inflammation, it create favorable conditions for liver tissue repair, effectively improving histological liver lesions and even achieving reversal of hepatic fibrosis.

Clinical studies have confirmed that chronic hepatitis B patients receiving long-term the product exhibit significantly reduced liver tissue inflammation scores and markedly improved hepatic fibrosis. In some patients, severe hepatic fibrosis can be reversed to mild fibrosis or even fully restored to normal. This histological improvement delays or halts the progression of liver disease, lowers the risk of liver cirrhosis, and safeguards long-term survival in chronic hepatitis B patients. Meanwhile, improved liver histology further restores liver function and enhances hepatic compensatory capacity.

Major complications of chronic hepatitis B include decompensated liver cirrhosis (e.g., ascites, gastrointestinal bleeding, hepatic encephalopathy) and hepatocellular carcinoma, which are the leading causes of clinical deterioration and death in patients. By long-term suppression of viral replication and improvement of hepatic fibrosis, the product significantly reduce the incidence of these complications.

On one hand, controlling the progression of hepatic fibrosis delays the onset of liver cirrhosis, lowering the probability of decompensated liver cirrhosis and avoiding life-threatening complications such as ascites, gastrointestinal bleeding and hepatic encephalopathy.

On the other hand, persistent viral replication is a critical risk factor for hepatocellular carcinoma. It potently and durably inhibit HBV replication, reducing chronic viral damage to hepatocytes and the risk of hepatocellular gene mutations, thereby significantly decreasing the likelihood of hepatocellular carcinoma in chronic hepatitis B patients. For high-risk patients with a family history of liver cancer, advanced age or severe hepatic fibrosis, long-term treatment with it effectively reduces the risk of liver cancer and improves patient survival rates.

As a first-line therapeutic agent for chronic hepatitis B, Entecavir Capsule relies on precise analytical methods for its quality control, in vivo drug concentration monitoring, and metabolic research. At present, analytical methods for this drug mainly focus on assay, related substances testing, and in vivo pharmacokinetic detection. High-performance liquid chromatography (HPLC) serves as the core technique, supplemented by other auxiliary methods to ensure accuracy, sensitivity, and reliability, supporting pharmaceutical quality control and rational clinical medication. The main analytical methods and key application points are described below.

With high separation efficiency, sensitivity, and specificity, HPLC is the most commonly used analytical method for entecavir Capsules. It is widely applied in drug assay, related substances testing, and in vivo concentration detection, and is also the mainstream method specified in pharmacopoeias. Chromatographic conditions should be adjusted according to the detection purpose to ensure satisfactory separation.

In the assay, reversed-phase HPLC is typically adopted, using a C18 chromatographic column as the stationary phase and a methanol-water or acetonitrile-water system as the mobile phase.

The flow rate is controlled at 0.8–1.0 mL/min, and the detection wavelength is set at 254 nm (the maximum absorption wavelength of entecavir). The content of entecavir in samples is calculated by the external standard method, with recoveries ranging from 95% to 105% and a precision RSD ≤ 2.0%. This enables accurate control of the active ingredient content in capsules and ensures consistent drug quality.

For related substances testing, gradient elution programs of the mobile phase are optimized to separate the main peak of baraclude from impurities such as synthetic intermediates and degradation products, ensuring the sensitivity of impurity detection and preventing impurities from compromising drug safety.In in vivo pharmacokinetic detection, plasma samples require pretreatment (e.g., liquid-liquid extraction, solid-phase extraction) to eliminate matrix interference. HPLC-UV or HPLC-MS is then used to determine plasma entecavir concentrations at different time points, providing a basis for adjusting clinical dosage regimens.

In addition to HPLC, two common auxiliary methods are used to overcome the limitations of a single technique.First, ultraviolet-visible spectrophotometry is simple and cost-effective. It is mainly used for rapid qualitative identification of entecavir raw materials and capsules. By measuring the absorption peak of samples at 254 nm and comparing it with reference standards, the authenticity of the drug can be preliminarily determined, making it suitable for rapid screening in primary laboratories.

Second, hyphenated mass spectrometry (HPLC-MS/MS) offers much higher sensitivity than conventional HPLC. It is mainly used for trace in vivo drug concentration detection and metabolite analysis. This method effectively eliminates biological matrix interference, with a limit of detection reaching the ng/mL level. It can accurately determine entecavir concentrations and metabolites in patient plasma and urine, providing precise data for optimizing dosage regimens in special populations (e.g., patients with hepatic or renal insufficiency), and is also applied in the study of drug metabolic mechanisms.